

ASX Announcement

24 February 2021

Cochlear receives FDA clearance and CE Mark accreditation for Cochlear™ Baha® 6 Max Sound Processor

Cochlear Limited, the global leader in implantable hearing solutions, announces it has received US Food and Drug Administration (FDA) clearance and CE Mark accreditation for the new Cochlear™ Baha® 6 Max Sound Processor, designed to improve hearing outcomes for people with single-sided deafness, conductive or mixed hearing loss.

With a fitting range of up to 55 dB SNHL (sensorineural hearing level) in the same small size as current 45 dB devices¹, the Baha 6 Max is the first of its kind: a premium-power bone conduction sound processor designed for powerful hearing performance. The Baha 6 Max is the first bone conduction sound processor to offer direct streaming from Apple® and Android™ devices². Direct streaming from Apple devices has been available in the Baha 5 Sound Processor since 2015. The new processor provides additional power in the smallest form^{1,3} and is designed to provide the clearest, richest and most natural sound possible, reducing the need to choose between hearing performance and size.

The Baha 6 Max Sound Processor will be launched across the US and Europe over the coming months.

For further information, please contact:

Analysts

Kristina Devon
Vice President Investor Relations
Email: kdevon@cochlear.com
Ph: + 61 2 9611 6691

Media

Jennifer Stevenson
Vice President Corporate Communications
Email: jstevenson@cochlear.com
Ph: +61 2 9611 6959

This announcement is authorised by the Continuous Disclosure Committee.

References

1. Land J. Comparison tech data Baha 6 Max, legacy and competition. Cochlear Bone Anchored Solutions AB, Sweden. 2020; D1762475.
2. The Cochlear Baha 6 Max Sound Processor is compatible with Apple and Android devices. For compatibility information, visit www.cochlear.com/compatibility.
3. Hoffman J. Subjective evaluation of clear rich and natural sound. Cochlear Bone Anchored Solutions AB, Sweden. 2020; D1788013.